European Market Overview
—
Healthcare data to drive decisions
comprehensive · accurate · accessible
Europe – Diagnostics
Real world hospital intelligence across 7,555 hospitals in 14 countries
Data spanning 5 to 7 years
Location Europe
Cases (selected) 0
Hospitals (selected) 0
1
Find the disease / indication
2
Choose the country market
Country volume (treated cases)
Select a disease to see where patients are treated
Select a disease to see the country breakdown.
3
Generate outputs
European Market Overview
✓
Pan-European cases, incidence, providers, trials & treatment mix.
Country Report
✓
Single combined report covering the selected country.
Five integrated modules + Excel hospital data
Includes
- Clinical Scope & Coding
- Treated Patient Reality
- Hospital Concentration & Tiering
- Regional Inequality & Access Signals
- Key Opinion Leaders & Market Influence
- Excel hospital data
0
—
EXECUTIVE SYNTHESIS
Treated Cases
—
Latest year
Hospitals
—
Treating centres
Tier 1 Case Share
—
Volume Trend
—
Market Snapshot
Loading…
Provider Structure
Loading…
Key Dynamics & Risks
- Loading…
Strategic Priorities
- Loading…
90-Day Action Plan
- Loading…
© PurpleXtra Limited
Executive Synthesis
European Market Overview
Market snapshot (Europe)
Geography
Europe
Indication
—
Treated cases (Europe)
—
Hospitals treating (Europe)
—
Built from hospital discharge activity (coded ICD-10), aggregated across participating providers.
Where the burden sits (country outliers)
Top countries by treated cases (latest)
Europe intensity
Cases per 100k population by country (latest year in dataset)
© PurpleXtra Limited
European Market Overview · Page 1
Cases and Incidence
Europe totals
Cases
—
Cases per 100k
—
Hospitals
—
Hospitals per 100k
—
Incidence outliers
Top & bottom countries by cases per 100k
Cases vs incidence (country scatter)
High volume ≠ high intensity
© PurpleXtra Limited
European Market Overview · Page 2
Hospitals and Providers
Provider footprint (Europe)
Hospitals per 100k (country outliers)
Tier segmentation (Europe)
Tier 1 / Tier 2 / Tier 3 hospital counts
Tier rules are defined by annual case volume thresholds in the Tiering module.
Commercial read
Medical read
© PurpleXtra Limited
European Market Overview · Page 3
Disease Analysis
ICD-10 breakdown
Subcodes (if present) or peer conditions
Treatment patterns (Europe)
Current treatment mix (high-level)
Full treatment detail is available in PurpleXtra modules + Excel exports.
© PurpleXtra Limited
European Market Overview · Page 4
Clinical Trials
Trial footprint (Europe)
Ongoing Trials (All 15 Countries)
—
Countries hosting trials
—
Trials by country
Where research activity concentrates
Top industry sponsors
Sponsor concentration (Europe)
© PurpleXtra Limited
European Market Overview · Page 5
Clinical Scope & Coding
ICD-10 Definition & Code Structure
—
—
Understanding how the indication maps to ICD-10 and how codes distribute across subtypes
Clinical Scope & Coding
ICD-10 Code Definition
ICD-10 Code
—
Disease Name
—
Common Names / Acronyms
—
Number of Subcodes
—
Total Cases
—
Hospitals Treating
—
ICD-10 Hierarchy
Chapter
—
↓
Group
—
↓
Selected Code
—
Coding Context
Loading coding context...
ICD-10 codes are used internationally to classify diseases and health conditions.
Code structure and usage may vary by country and healthcare system.
© PurpleXtra Limited
Clinical Scope & Coding · Page 1
Subcode Distribution
Subcode Volume
Cases by 4-digit ICD-10 subcode
Subcode Share
Proportion of total activity
Subcode Detail
Loading subcode analysis...
© PurpleXtra Limited
Clinical Scope & Coding · Page 2
Related Codes & Coding Guidance
Peer Codes in Group
ICD-10 codes :
Group Comparison Table
Coding Guidance
Loading coding relationships...
Note: Coding practices vary by institution and country.
PurpleXtra data reflects actual coded hospital activity, not clinical diagnosis alone.
© PurpleXtra Limited
Clinical Scope & Coding · Page 3
Treated Patient Reality
Volumes, Trends & Burden Signals
—
—
Real-world hospital activity patterns showing treatment volumes, demographic distribution, and care pathways
Treated Patient Reality
Total Treated Population
Total Cases (Latest Year)
—
—
National Incidence
Cases per 100,000 Population
—
Latest available data
Total Cases by Year
Historical treatment volume trends
Key Trends Analysis
- Loading trend analysis...
© PurpleXtra Limited
Treated Patient Reality · Page 1
Patient Demographics
Population by Age Group and Sex
Population distribution showing male/female breakdown
Demographic Insights
- Loading demographic analysis...
Sources: Population data analysis
© PurpleXtra Limited
Treated Patient Reality · Page 2
Patient Journey & Healthcare Access
Typical Patient Journey
- Loading patient journey information...
© PurpleXtra Limited
Treated Patient Reality · Page 3
Hospital Distribution by Tier
Treatment capacity across hospital tiers
Tier 1 Hospitals
—
High volume centers
Tier 2 Hospitals
—
Medium volume
Tier 3 Hospitals
—
Lower volume
Healthcare Access Analysis
- Loading healthcare access analysis...
© PurpleXtra Limited
Treated Patient Reality · Page 4
Hospital Concentration & Tiering
Provider Landscape & Market Structure
—
—
Hospital tier distribution, concentration metrics, and targeting intelligence for pharma commercial strategy
Hospital Concentration & Tiering
Total Hospitals
—
Total Cases
—
Tier 1 Case Share
—
Top 10 Case Share
—
Hospital Case Distribution (Pareto)
The Pareto curve shows cumulative case concentration. Tier I hospitals (0-70% of cases) represent high-volume centers, Tier II (70-90%) medium-volume, and Tier III (90-100%) lower-volume providers.
Tier Summary
Loading tier data...
Market Concentration Insights
- Loading strategic insights...
© PurpleXtra Limited
Hospital Concentration & Tiering · Page 1
Hospital Concentration & Tiering
Top Regions by Case Volume
Loading hospital data...
Geographic Concentration by City
Loading city data...
Account Prioritization Insights
- Loading targeting insights...
© PurpleXtra Limited
Hospital Concentration & Tiering · Page 2
Hospital Concentration & Tiering
KOL Center Identification
- Loading KOL insights...
Market Access Strategy
- Loading market access insights...
Resource Allocation & Field Force Strategy
- Loading resource allocation insights...
© PurpleXtra Limited
Hospital Concentration & Tiering · Page 3
Regional Inequality & Access Signals
Geographic Disparities & Service Access Analysis
—
—
Identify where most patients are treated, find regions with unmet need, and deploy your team for maximum impact
Regional Inequality & Access Signals
Regions Analyzed
—
Top Region Share
—
Concentration Index
—
Regional Case Distribution
Access Inequality (Cases vs Hospitals)
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 1
Regional Inequality & Access Signals
Regional Summary
Key Disparities
- Loading insights...
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 2
Regional Inequality & Access Signals
City-Level Access Analysis
Top Cities by Volume
Geographic Coverage Gaps
- Loading gap analysis...
Travel Distance Implications
- Loading travel analysis...
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 3
Regional Inequality & Access Signals
Hospital Capacity Pressure
High-Volume Centres
- Loading pressure analysis...
Service Expansion Opportunities
- Loading expansion analysis...
Resource Allocation Recommendations
- Loading recommendations...
© PurpleXtra Limited
Regional Inequality & Access Signals · Page 4
Key Opinion Leaders & Market Influence
Research Activity & KOL Landscape
—
—
Identify research-active sites, trial investigators, and early adopters for pre-launch engagement
Key Opinion Leaders & Market Influence
Active Trials
—
Recent Trials
—
Started in 2025
Total Hospitals
—
© PurpleXtra Limited
Key Opinion Leaders & Market Influence · Page 1
Key Opinion Leaders & Market Influence
© PurpleXtra Limited
Key Opinion Leaders & Market Influence · Page 2
Key Opinion Leaders & Market Influence
Europe Publications
—
Total papers on disease
Country Publications
—
Total papers from country
Recent Publications
—
Last 12 months (country)
Key Opinion Leaders - Publications
© PurpleXtra Limited
Key Opinion Leaders & Market Influence · Page 3
Key Opinion Leaders & Market Influence
Strategic Summary
© PurpleXtra Limited
Key Opinion Leaders & Market Influence · Page 4
METHODS & DATA SOURCES
Transparency note — how this report was built
Data Provenance
All quantitative outputs in this report derive from structured, auditable data sources. No case counts, hospital figures, or tier assignments are estimated, projected, or modelled. Diagnostic statistics are obtained from national and regional government bodies and hospital organisations, accessed using the national Freedom of Information legislation in each country. Hospital records are drawn from PurpleXtra's proprietary hospital database, where every facility has been individually researched and verified.
| Data Domain | Primary Source | Scope | Access Method |
|---|---|---|---|
| Diagnostic statistics | National & regional government health agencies; hospital organisations | ICD-10 coded hospital activity across 15 European countries; annual volumes by facility | Freedom of Information requests under national FOI legislation |
| Hospital database | PurpleXtra proprietary hospital database | Name, address, region, bed count, contact details; every hospital individually researched | Continuous primary research; validated quarterly |
| Population statistics | Eurostat; Office for National Statistics (United Kingdom) | Total population by country and year for incidence rate calculation | Published open data; annual updates |
| Clinical trials | ClinicalTrials.gov v2 API (U.S. National Library of Medicine) | Registered trials by MeSH condition; status, sponsors, country site locations | Live API; results cached 24 hours |
| Publication & KOL analysis | PubMed / MEDLINE via NCBI E-utilities API | Indexed peer-reviewed publications; author affiliations; last 12 months focus | Live API; results cached 24 hours |
| Disease taxonomy | WHO ICD-10 classification; NLM MeSH vocabulary | Code-to-description mapping; MeSH linkage for trial & publication queries | Versioned; updated with WHO releases |
| Treatment landscape | Clinical guidelines (ESMO, NICE, EMA and equivalents); published literature | European treatment patterns, approved therapies, standard-of-care protocols | AI-synthesised from published clinical sources; cited in report |
Hospital Tiering Methodology
Hospitals are ranked by descending case volume. Tier I comprises the fewest hospitals whose cumulative caseload reaches 70% of the national total. Tier II extends coverage to 90%. Tier III contains the remaining long-tail facilities. Thresholds are applied consistently across all 15 countries, enabling direct cross-market comparison of provider concentration.
AI-Assisted Analysis
Narrative insights, strategic commentary, and the Executive Synthesis are generated by Anthropic Claude, prompted exclusively with the structured data presented in this report. The model does not inject external assumptions. Treatment landscape summaries are AI-synthesised from published clinical guidelines and peer-reviewed sources, which are cited individually within the relevant report sections.
Coverage & Known Limitations
The 15-country panel (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom) covers approximately 85% of the EU/EEA pharmaceutical market by value.
Diagnostic data captures treated inpatient episodes and may under-represent outpatient-only management or private-sector activity. Data availability may vary between countries depending on FOI response timelines. Multi-country clinical trials are counted once per country but deduplicated in pan-European totals.
© PurpleXtra Limited
Methods & Data Sources
PurpleXtra Limited
Email: info@purplextra.com
Web: www.purplextra.com
Registered in England & Wales · Company No. 13518421
© PurpleXtra Limited. All rights reserved.
Generating Report
Initialising…
0 %
Subscription required
Generating reports requires a PurpleXtra subscription. You're welcome to explore the interface, and download our sample files to see the quality and depth of what we deliver.
Sample covers Cystic Fibrosis in France — the same reference dataset shown in our product demos.